An observational study in Drug-Resistant Epilepsy and Brain-Body Physiological Coupling, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Xuanwu Hospital, Beijing · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.
Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one is the only one that started in 2026, is one of 3 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 15th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
Xuanwu Hospital, Beijing · Sites in China
Ages 6–60
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
By country, each count listing its studies:
Of the 67 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 40 (60%) stop at 75 or younger; 26 take children under 18; 6 take healthy volunteers.
This study: 14 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 86 across 45 observational studies indexed under Drug Resistant Epilepsy.
Median enrollment 13 across the 12 interventional studies, 30 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
1 of the studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07305311Xuanwu Hospital, BeijingCharacterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG | 2027-01-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study aims to understand how electrical activity in the brain is related to activity in the stomach, heart, respiratory system, blood pressure, and glucose levels in people with drug-resistant epilepsy undergoing stereoelectroencephalography (SEEG) monitoring as part of their clinical care.
Researchers will collect synchronized recordings of brain activity and available body signals, including surface electrogastrography, electrocardiography and heart rate, abdominal respiratory movement, continuous glucose monitoring, and noninvasive blood pressure. The study will examine brain-body relationships during wakefulness, sleep, meals, seizures, and routine electrical stimulation or functional mapping performed for clinical purposes.
All decisions about SEEG implantation, electrical stimulation, functional mapping, medication, and other clinical care are made independently by the treating clinical team. The research protocol does not assign, add, or modify any electrical stimulation or treatment. The study only records and analyzes physiological responses associated with routine clinical care and naturally occurring physiological states.
The study population consists of patients aged 14 to 60 years with drug-resistant epilepsy who are admitted to Xuanwu Hospital, Capital Medical University, for clinically indicated stereoelectroencephalography monitoring. Eligible patients will be enrolled prospectively during inpatient monitoring. Participants may contribute synchronized SEEG and available gastric, cardiac, respiratory-movement, blood pressure, and glucose data. Clinical treatment, electrode implantation, medication changes, seizure monitoring, and intracranial electrical stimulation or functional mapping are determined independently by the treating clinical team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gastrectomy, gastric electrical stimulation devices, or established gastroparesis will not automatically exclude a participant from the overall cohort. These participants may contribute to other eligible study modules but will be excluded from the primary brain-stomach analysis or analyzed as a special physiology subgroup.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients aged 14 to 60 years with drug-resistant epilepsy who undergo stereoelectroencephalography monitoring based on clinical indications. Synchronized brain and peripheral physiological signals are observed during natural physiological states, clinical seizures, and routine electrical stimulation or functional mapping. The study does not assign or modify SEEG implantation, electrical stimulation, medication, or other clinical care.
Procedure: Clinically Indicated Stereoelectroencephalography Monitoring · Procedure: Clinically Indicated Intracranial Electrical Stimulation and Functional Mapping
Participants undergo SEEG monitoring as part of routine clinical evaluation for drug-resistant epilepsy. The research study records and analyzes SEEG together with available gastric, cardiac, respiratory, blood pressure, and glucose signals. The decision to perform SEEG and the placement of electrodes are determined independently by the clinical care team.
Some participants may undergo intracranial electrical stimulation or functional mapping as part of routine clinical care. Stimulation targets, timing, parameters, and clinical indications are determined independently by the treating clinical team. The research protocol does not assign, add, or modify stimulation and only observes associated physiological responses.
Mean Heartbeat-Evoked SEEG Potential Amplitude at 200-500 Milliseconds After the ECG R Peak
Heartbeat-evoked potentials will be measured from stereoelectroencephalography (SEEG) recordings time-locked to R peaks detected by simultaneous electrocardiography (ECG). The outcome is the mean signed potential amplitude from 200 to 500 milliseconds after the R peak, relative to the mean potential from 200 to 50 milliseconds before the R peak, expressed in microvolts (µV). Eligible heartbeats will be averaged within each segment and bipolar derivation. Derivations with prominent cardiac-field artifacts will be excluded. Results will be summarized by anatomical region and physiological state within each participant before cohort-level analysis. Pseudo-R-peak analyses will assess responses beyond chance.
Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.
Circular-Linear Correlation Coefficient Between ECG-Derived Cardiac Phase and SEEG Frequency-Band Amplitude
Cardiac phase will be derived from successive R peaks detected by electrocardiography (ECG). Neural amplitude will be derived from the Hilbert envelope of bipolar stereoelectroencephalography (SEEG) recordings in delta (1-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz), low-gamma (30-70 Hz), and high-frequency (70-170 Hz) bands, excluding line-noise frequencies. Log-transformed amplitude will be regressed on sine and cosine of cardiac phase. The outcome is the multiple correlation coefficient R, calculated as the square root of explained variance (R²); it is dimensionless and ranges from 0 to 1. Higher values indicate stronger phase-dependent amplitude modulation. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Autocorrelation-preserving surrogates will assess coupling beyond chance.
Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.
Circular-Linear Correlation Coefficient Between Cutaneous EGG-Derived Gastric Phase and SEEG Frequency-Band Amplitude
Gastric slow-wave phase will be obtained from cutaneous electrogastrography (EGG), recorded using abdominal surface electrodes connected to the SEEG acquisition system. An individually verified gastric peak within 2-4 cycles per minute will define phase extraction. SEEG frequency-band amplitude will be obtained from bipolar recordings in delta, theta, alpha, beta, low-gamma, and high-frequency bands. Log-transformed amplitude will be regressed on sine and cosine of gastric phase. The outcome is the multiple correlation coefficient R, calculated as the square root of R²; it is dimensionless and ranges from 0 to 1. Higher values indicate stronger coupling. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Autocorrelation-preserving surrogates will assess coupling beyond chance. Segments without a verified gastric rhythm will not contribute coupling estimates.
Time frame: During 20-minute analysis segments in awake fasting, postprandial, and non-rapid eye movement sleep states, collected over 1-14 days of inpatient SEEG monitoring.
Circular-Linear Correlation Coefficient Between Abdominal Respiratory-Movement Proxy Phase and SEEG Frequency-Band Amplitude
Respiratory-movement proxy phase will be extracted from the 0.1-0.5 Hz component of abdominal surface-electrode signals recorded by the SEEG acquisition system. This is an abdominal-movement proxy, not an independent airflow or respiratory-belt measurement. SEEG frequency-band amplitude will be obtained from bipolar recordings in delta, theta, alpha, beta, low-gamma, and high-frequency bands. Log-transformed amplitude will be regressed on sine and cosine of respiratory-proxy phase. The outcome is the multiple correlation coefficient R, calculated as the square root of R²; it is dimensionless and ranges from 0 to 1. Higher values indicate stronger coupling. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Only segments with identifiable respiratory cycles will be analyzed; autocorrelation-preserving surrogates will assess coupling beyond chance.
Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.
Change in Mean Arterial Pressure During the First 10 Minutes After Clinically Indicated Intracranial Electrical Stimulation
Mean arterial pressure (MAP) will be measured in millimeters of mercury (mmHg) using a CNSystems noninvasive continuous beat-to-beat blood pressure monitor. The outcome is mean MAP during 0-10 minutes after stimulation ends minus mean MAP during the 10 minutes immediately before stimulation begins, expressed in mmHg. Only valid recorded beats will contribute to each interval mean. Exposure-level changes will be summarized within each participant and stimulation target before cohort-level analysis. Stimulation is performed solely for clinically indicated functional mapping or other clinical care; the research protocol does not assign or modify stimulation.
Time frame: From 10 minutes before stimulation begins to 10 minutes after stimulation ends, within a recording window extending from 15 minutes before to 30 minutes after each exposure during inpatient SEEG monitoring.
Cumulative 0-120-Minute Distributed-Lag Regression Coefficient for SEEG Frequency-Band Power and CGM-Measured Interstitial Glucose
Interstitial glucose concentration will be measured in mmol/L using a MicroTech continuous glucose monitor (CGM) recording once per minute. Frequency-band power will be derived from bipolar stereoelectroencephalography (SEEG) in delta, theta, alpha, beta, low-gamma, and high-frequency bands. SEEG log power will be summarized in 5-minute bins and standardized within each participant; CGM values will be averaged in matching bins. A distributed-lag mixed model will relate earlier SEEG log power to glucose concentration at lags of 0-120 minutes. The outcome is the sum of lag-specific regression coefficients, expressed in mmol/L per 1-standard-deviation sustained increase in SEEG log power across the lag window. Results will be reported by anatomical region and frequency band. Models will account for participant baseline, time of day, sleep, meals, medication, seizures, and serial autocorrelation.
Time frame: During 1-14 days of inpatient SEEG monitoring, using 5-minute analysis bins and SEEG-to-glucose lags of 0-120 minutes.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.